University of Rochester researchers have unveiled an innovative online tool, harnessing artificial intelligence (AI), which enables individuals with Parkinson’s disease (PD) to assess the severity of their symptoms remotely and swiftly.
Researchers have identified a protein, alpha 5 integrin, which is linked to the progression of amyotrophic lateral sclerosis (ALS). The protein was consistently found in high concentrations around damaged motor neurons in ALS patients and mouse models. By blocking this protein in mice, the disease's progression was slowed, and motor skills improved.
Researchers from UC Davis and the University of Oxford have developed SparkMaster 2, a cutting-edge software to automatically analyze calcium activity in cells. This breakthrough promises to significantly aid medical research. New Software Offers Insight into Calcium's Role in Heart Diseases and Aids Medical Research
Moderna's newly updated COVID-19 vaccine demonstrates promising efficacy against emerging variants, according to recent trial data. The updated shot is awaiting FDA approval for fall deployment.
Biohaven, has unveiled optimistic data from its recent Phase 1 EEG biomarker study of BHV-7000, a novel epilepsy treatment. The research centered on assessing qualitative EEG changes post-administration of BHV-7000 in different doses, providing an insight into its potential effects.
A newly discovered mutation of the avian flu virus in Chinese poultry farms has caused worldwide alarm, as scientists warn it could increase the risk of the virus transmitting to humans on a wider scale. These changes could potentially make the disease more transmissible among humans.
The U.S. Food and Drug Administration recently published a report highlighting the benefits and risks of emerging augmented and virtual reality (AR/VR) medical devices. While these tools offer advancements in medical care delivery, the FDA emphasized several potential risks.
BioMarin Pharmaceutical has introduced its gene therapy, Roctavian, in Europe, marking a significant breakthrough for severe haemophilia A patients. The new gene therapy, first administered in Germany, enables patients to naturally produce the clotting factor VIII protein.
Roche has announced encouraging results from a Phase 3 trial for its drug, Alecensa, in treating early-stage non-small cell lung cancer (NSCLC) with ALK-positive tumors. The ALINA trial showed that Alecensa might be more effective than standard chemotherapy.
FDA has given Orphan Drug Designation to Faron Pharmaceuticals' bexmarilimab, a treatment designed for acute myeloid leukaemia. This breakthrough in drug designation is set to bring advantages in clinical development and commercialisation,
A groundbreaking advance in the fight against the opioid epidemic is unfolding at the University of Montana. Vaccines targeting fatal opioids, fentanyl and heroin, are set to commence human trials in early 2024. Researchers, are on the brink of testing vaccines designed to prevent fentanyl and heroin overdoses in humans.
AbbVie has applied to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval for a new indication of risankizumab (Skyrizi) for treating moderately to severely active ulcerative colitis.
The European Commission has approved Merck’s Keytruda, in combination with other drugs, for the treatment of gastric or gastroesophageal junction adenocarcinoma. Keytruda, an anti-PD-1 therapy, is the inaugural immunotherapy to be endorsed in the EU for this group of patients.
Researchers from the University of California have issued a warning about the potential dangers of GLP-1RAs, commonly used in weight loss drugs such as Ozempic and Wegovy - for children and adolescents. The drugs, increasingly used to treat childhood obesity and type 2 diabetes, may have unintended and adverse impacts on pediatric health.
Regard, an AI software company, has collaborated with OpenAI to introduce new functionalities in their core product and launch a chatbot named Max, powered by OpenAI's GPT-4. Aimed at revolutionizing clinical workflows, these features are being tested across multiple health systems in the U.S.
The U.S. Food and Drug Administration (FDA) has enhanced the approval parameters for Bristol Myers Squibb's Reblozyl, paving the way for its broader application in treating myelodysplastic syndromes (MDS).
A Stanford-backed study on the BeMe Health app, tailored for teens, highlights substantial user engagement and positive mental health impact. Of over 13,000 participants, a significant majority screened positively for depression and anxiety, finding solace in the platform's evidence-based content.
According to the phase 3 STEP HFpEF study published in The New England Journal of Medicine, the popular diabetes and weight loss drug Wegovy (semaglutide) significantly reduced symptoms of a common type of heart failure and led to increased weight loss in obese individuals.
The Food and Drug Administration (FDA) has given the green light to Novartis for its drug Tyruko, a biosimilar of Biogen’s blockbuster Tysabri, paving the way for more competitive pricing in the US market.
Recent research unveils ChatGPT's groundbreaking potential in the medical field. The AI chatbot demonstrates a notable 72% accuracy rate in clinical decisions. The study shows how ChatGPT is reshaping modern clinical practices.